Cara Therapeutics (CARA) – Globe Newswire
-
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
-
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
-
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
-
Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
-
Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis
-
Cara Therapeutics Reports Third Quarter 2023 Financial Results
-
Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty
-
Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023
-
Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients
-
Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
-
Cara Therapeutics Reports Second Quarter 2023 Financial Results
-
Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors
-
Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
-
Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023
-
Cara Therapeutics to Present at the Jefferies Healthcare Conference
-
Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
-
Cara Therapeutics Reports First Quarter 2023 Financial Results
-
Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023
-
Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023
-
Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
-
Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
-
Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report
-
Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report
-
Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
-
Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
-
Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
-
Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
-
Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine
-
Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine
-
Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023
-
Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023
-
Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
-
Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
-
KemPharm Announces Appointment of Christopher Posner as New Independent Director
-
Cara Therapeutics Reports Third Quarter 2022 Financial Results
-
Cara Therapeutics Reports Third Quarter 2022 Financial Results
-
Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors
-
Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors
-
Cara Therapeutics to Present at Upcoming Investor Conferences
-
Cara Therapeutics to Present at Upcoming Investor Conferences
-
Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
-
Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
-
Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan
-
Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan
-
Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer
-
Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer
-
Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress
-
Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress
-
Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Back to CARA Stock Lookup